Establishment Labs Holdings Inc. (NASDAQ:ESTA) Stock Position Lessened by JW Asset Management LLC

JW Asset Management LLC lessened its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 3.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,092,485 shares of the company’s stock after selling 100,000 shares during the period. Establishment Labs accounts for approximately 67.7% of JW Asset Management LLC’s portfolio, making the stock its largest holding. JW Asset Management LLC owned approximately 11.04% of Establishment Labs worth $142,471,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of ESTA. Assenagon Asset Management S.A. purchased a new stake in shares of Establishment Labs in the fourth quarter valued at about $12,898,000. Raymond James Financial Inc. acquired a new position in shares of Establishment Labs in the fourth quarter valued at approximately $5,494,000. Stonepine Capital Management LLC acquired a new position in shares of Establishment Labs in the third quarter valued at approximately $3,245,000. Bamco Inc. NY raised its position in shares of Establishment Labs by 13.6% in the third quarter. Bamco Inc. NY now owns 489,386 shares of the company’s stock valued at $21,176,000 after buying an additional 58,611 shares during the last quarter. Finally, Mudita Advisors LLP raised its position in shares of Establishment Labs by 19.0% in the third quarter. Mudita Advisors LLP now owns 354,801 shares of the company’s stock valued at $15,352,000 after buying an additional 56,700 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $36.69 on Tuesday. Establishment Labs Holdings Inc. has a one year low of $28.16 and a one year high of $60.12. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The company has a 50 day moving average price of $37.19 and a 200 day moving average price of $41.29. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -14.22 and a beta of 0.95.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.34). Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The company had revenue of $44.51 million for the quarter, compared to analyst estimates of $44.45 million. Sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Stephens reissued an “overweight” rating and issued a $52.00 price objective on shares of Establishment Labs in a research report on Thursday, March 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Establishment Labs presently has a consensus rating of “Moderate Buy” and an average price target of $57.40.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.